[go: up one dir, main page]

WO2004094465A3 - Synthetic molecules that mimic chemokines - Google Patents

Synthetic molecules that mimic chemokines Download PDF

Info

Publication number
WO2004094465A3
WO2004094465A3 PCT/US2004/012708 US2004012708W WO2004094465A3 WO 2004094465 A3 WO2004094465 A3 WO 2004094465A3 US 2004012708 W US2004012708 W US 2004012708W WO 2004094465 A3 WO2004094465 A3 WO 2004094465A3
Authority
WO
WIPO (PCT)
Prior art keywords
mimic
chemokines
synthetic molecules
polypeptides
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/012708
Other languages
French (fr)
Other versions
WO2004094465A2 (en
WO2004094465A8 (en
Inventor
Ziwei Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Illinois at Urbana Champaign
Original Assignee
University of Illinois at Urbana Champaign
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Illinois at Urbana Champaign filed Critical University of Illinois at Urbana Champaign
Publication of WO2004094465A2 publication Critical patent/WO2004094465A2/en
Publication of WO2004094465A8 publication Critical patent/WO2004094465A8/en
Anticipated expiration legal-status Critical
Publication of WO2004094465A3 publication Critical patent/WO2004094465A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention is directed to synthetic polypeptides that mimic chemokine function. These polypeptides are useful for the treatment of chemokine-related disorders, as well as the treatment and prevention of HIV infection. Novel synthetic methods for these polypeptides are also provided.
PCT/US2004/012708 2003-04-23 2004-04-23 Synthetic molecules that mimic chemokines Ceased WO2004094465A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46471403P 2003-04-23 2003-04-23
US60/464,714 2003-04-23

Publications (3)

Publication Number Publication Date
WO2004094465A2 WO2004094465A2 (en) 2004-11-04
WO2004094465A8 WO2004094465A8 (en) 2004-12-23
WO2004094465A3 true WO2004094465A3 (en) 2006-03-02

Family

ID=33310942

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/012708 Ceased WO2004094465A2 (en) 2003-04-23 2004-04-23 Synthetic molecules that mimic chemokines

Country Status (1)

Country Link
WO (1) WO2004094465A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2336245T3 (en) * 2005-04-08 2010-04-09 Lonza Ag PEPTIDIC SYNTHESIS OF HELICES ALFA ON PEG RESIN.
US8628750B2 (en) 2006-02-27 2014-01-14 Technische Universitat Munchen Cancer imaging and treatment
US7696309B2 (en) * 2006-10-23 2010-04-13 The Brigham And Women's Hospital, Inc. Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
EP2053060A1 (en) * 2007-10-24 2009-04-29 Protaffin Biotechnologie AG SDF-1-based glyocosaminoglycan antagonists and methods of using same
US8921415B2 (en) 2009-01-29 2014-12-30 Mapi Pharma Ltd. Polymorphs of darunavir
MX2012008627A (en) 2010-01-28 2012-09-21 Mapi Pharma Ltd Process for the preparation of darunavir and darunavir intermediates.
WO2011106234A1 (en) 2010-02-25 2011-09-01 Provasculon, Inc. Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
WO2012170495A1 (en) 2011-06-07 2012-12-13 Provasculon, Inc. Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1
AU2014280191B2 (en) * 2013-06-12 2018-10-11 Pharis Biotec Gmbh Peptides with antagonistic activities against natural CXCR4
CN107325187B (en) * 2017-07-19 2021-11-09 黄子为 Polypeptide with CXCR4 protein agonistic activity and application and pharmaceutical composition thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2751658A1 (en) * 1996-07-26 1998-01-30 Pasteur Institut USE OF A LESTR / FUSIN / CXCR4 RECEIVER CHEMOKINE (SDF-1) LIGAND TO PREVENT OR TREAT HIV-TYPE INFECTION
WO1999020759A1 (en) * 1997-10-22 1999-04-29 Genetics Institute, Inc. Chemokines with amino-terminal modifications
WO1999047158A2 (en) * 1998-03-13 1999-09-23 The University Of British Columbia Therapeutic chemokine receptor antagonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2751658A1 (en) * 1996-07-26 1998-01-30 Pasteur Institut USE OF A LESTR / FUSIN / CXCR4 RECEIVER CHEMOKINE (SDF-1) LIGAND TO PREVENT OR TREAT HIV-TYPE INFECTION
WO1999020759A1 (en) * 1997-10-22 1999-04-29 Genetics Institute, Inc. Chemokines with amino-terminal modifications
WO1999047158A2 (en) * 1998-03-13 1999-09-23 The University Of British Columbia Therapeutic chemokine receptor antagonists

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHEN WEN-JI ET AL: "Recombinant human CXC-chemokine receptor-4 in melanophores are linked to Gi protein: Seven transmembrane coreceptors for human immunodeficiency virus entry into cells", MOLECULAR PHARMACOLOGY, vol. 53, no. 2, February 1998 (1998-02-01), pages 177 - 181, XP002325707, ISSN: 0026-895X *
LOETSCHER ET AL: "N-TERMINAL PEPTIDES OF STROMAL CELL-DERIVED FACTOR WITH CXC CHEMOKINE RECEPTOR 4 AGONIST AND ANTAGONIST ACTIVITIES", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 273, no. 35, 28 August 1998 (1998-08-28), pages 22279 - 22283, XP002115696, ISSN: 0021-9258 *
MERZOUK A ET AL: "RATIONAL DESIGNING OF CXCR-4 AGONISTS AND ANTAGONISTS: SYNTHESIS OF NOVEL CYCLAM DERIVATIVES OF STROMAL CELL-DERIVED FACTOR (SDF-1)", PEPTIDES: THE WAVE OF THE FUTURE: PROCEEDINGS OF THE INTERNATIONAL AND THE AMERICAN PEPTIDE SYMPOSIUM, 9 June 2001 (2001-06-09), pages 789 - 790, XP009046707 *
THIERRY ANNE-CHRISTINE ET AL: "Long synthetic peptides as biologically active proteins: The example of the chemokines", BIOLOGICALS, ACADEMIC PRESS LTD., LONDON, GB, vol. 29, no. 3-4, September 2001 (2001-09-01), pages 259 - 263, XP002274174, ISSN: 1045-1056 *

Also Published As

Publication number Publication date
WO2004094465A2 (en) 2004-11-04
WO2004094465A8 (en) 2004-12-23

Similar Documents

Publication Publication Date Title
WO2006124748A3 (en) Multicyclic compounds and methods of their use
WO2004041203A3 (en) Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
WO2004103960A3 (en) Compounds and uses thereof
WO2003097794A3 (en) Universal-tagged oligonucleotide primers and methods of use
WO2002030358A3 (en) Modulation of ccr4 function
WO2004006858A3 (en) Compounds, compositions, and methods employing same
WO2006073968A3 (en) Derivatized 3,4-alkylenedioxythiophene monomers, methods of making them, and use thereof
WO2007076423A3 (en) INHIBITORS OF Akt ACTIVITY
NO20034056D0 (en) Proliferative diseases
WO2005012243A3 (en) Substituted indole-o-glucosides
MXPA04002982A (en) Pyrrolidinone derivatives.
WO2005063734A3 (en) Substituted thiophenes
WO2004069152A3 (en) Δ4,5 glycuronidase and uses thereof
NO20035025L (en) Use of osteopontin for the treatment and / or prevention of neurological diseases, as well as a pharmaceutical composition comprising osteopontin or an antagonist with osteopontin activity.
GB0111186D0 (en) Novel compounds
WO2006089665A3 (en) Active ingredient combinations having insecticide and acaricide properties
PL374080A1 (en) Processes for the preparation of fibrinogen
EE200400005A (en) A tablet containing at least two distinct segments and its use
WO2005074598A3 (en) Nitroxyl progenitor compounds and methods of use
WO2004094465A3 (en) Synthetic molecules that mimic chemokines
BR0008292A (en) Mevinoline derivatives
WO2004081229A3 (en) Use of bv8 and/or eg-vegf to promote hematopoiesis
WO2004065406A3 (en) Rantes-derived peptides with anti-hiv activity
WO2004026892A3 (en) Fragmentation of dna
WO2003042240A3 (en) Polypeptides of pseudomonas aeruginosa

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 45/2004 UNDER "PUBLISHED" DELETE "SEQUENCE LISTING PART OF DESCRIPTION PUBLISHED SEPARATELY IN ELECTRONIC FORM AND AVAILABLE UPON REQUEST FROM THE INTERNATIONAL BUREAU"

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase